Auspex Pharma's movement disorder drug succeeds late-stage trial
December 16, 2014 at 16:30 PM EST
Dec 16 (Reuters) - Auspex Pharmaceuticals Inc said its drug for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study.
